Experimental findings demonstrate that trophoblast extracellular vesicles promote CD169+ macrophage recruitment, suggesting a new therapeutic strategy against ovarian tumours.
Placental-derived trophoblast EVs may act as an immune modulator, specifically in the presence of tumours, through promoting CD169⁺ macrophage recruitment to the tumour site, resulting in an anti-ovarian tumour response. These findings suggest the potential of trophoblast EVs as a novel immune-based therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: